Share This

Related Topics News -

     
 Detail   |   Print    Next page > 
     
藥明巨諾瑞基奧侖賽注射液新適應症上市申請獲受理
2025-05-28T  
《業績》藥明巨諾全年虧損收窄至5.91億元人民幣
2025-03-27T  
藥明巨諾-B行政總裁兼任主席
2025-03-16T  
藥明系股份全線下挫 藥明生物及藥明巨諾分別挫8.5%及11.2%
2025-02-24T  
內地發布穩外資行動方案:研究完善醫藥領域開放政策 打造「投資中國」品牌
2025-02-19T  
國家醫保局:今年將開展第11批國家藥品集採和第6批耗材集採
2025-01-17T  
藥明巨諾治療淋巴瘤藥物獲國家藥監局突破性治療藥物認定
2025-01-10T  
《大行》里昂:美國生物安全法未包含在國防授權法案中 意味2024年通過可能性大幅降低
2024-12-09T  
《生物安全法》未列入美國國防授權法案最終文本 藥明康德及藥明生物升近8%
2024-12-09T  
國家醫保局:協議期內談判藥品累計為患者減負逾8,800億人幣
2024-11-28T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.